Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Adaptimmune Therapeutics plc ADAP

Healthcare Biotechnology
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. It develops T-cell therapies for solid tumors and has reported responses in multiple solid tumor indications. Its platform helps to identify cancer targets, find and develop cell therapy candidates active against those targets and produce... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ADAP)

Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated

Newsfile 6 days ago

Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet

Newsfile March 27, 2024

Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates

Newsfile March 6, 2024

Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise

Newsfile February 27, 2024

Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024

Newsfile February 21, 2024

Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review

Newsfile January 31, 2024

Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference

Newsfile January 4, 2024

Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma

Newsfile December 6, 2023

Adaptimmune Receives Transfer of IND for Lete-cel Program

Newsfile November 29, 2023
View More News ››

Opinion & Analysis (NDAQ:ADAP)

Adaptimmune Shares Triple as SPEAR T-cell Platform Delivers Initial Responses ...

Streetwise Reports January 14, 2020

Coverage Initiated on Biotech Whose Therapies 'Can Compete with CAR-Ts'

Streetwise Reports June 10, 2019
View More Opinion ››

Bullboard Posts (NDAQ:ADAP)

Adaptimmune to Report Q4 and Full Year 2023 Financial and Bu

Breaking News: $ADAP Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024Philadelphia,...
whytestocks - February 21, 2024

Some giddy yapping here....

Will see how they go.  Expensive, but helpful treatment today.....maybe a future here.
hoffbag - August 24, 2022

still holding this stock

things are picking up nicely,so glta shareholders.
coolfooldumbguy - January 14, 2020

RE:it's a buy today for me

Yes nice breakout and HUGHE VOLUME!!!! This stock gert history at 14$ per shares. With volume like this and some good news...
JPlantard - January 13, 2020

it's a buy today for me

at $2.57 per share,big promises and results coming,so glta.
coolfooldumbguy - January 13, 2020
View more Bullboard ››

Multi-Metal Development Ltd

Multi-Metal Development Ltd

Multi-Metal Development Ltd is a Canada-based mining company. The Company's projects consist of CuMo Project in Idaho and ...
View More »